HK1198703A1 - Hpv chimaeric particle - Google Patents

Hpv chimaeric particle Download PDF

Info

Publication number
HK1198703A1
HK1198703A1 HK14112143.5A HK14112143A HK1198703A1 HK 1198703 A1 HK1198703 A1 HK 1198703A1 HK 14112143 A HK14112143 A HK 14112143A HK 1198703 A1 HK1198703 A1 HK 1198703A1
Authority
HK
Hong Kong
Prior art keywords
hpv
chimaeric
particle
vlp
relates
Prior art date
Application number
HK14112143.5A
Other languages
English (en)
Chinese (zh)
Inventor
Peter Rybicki Edward
Isabel Hitzeroth Inga
Original Assignee
University Of Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Cape Town filed Critical University Of Cape Town
Publication of HK1198703A1 publication Critical patent/HK1198703A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK14112143.5A 2011-12-01 2012-12-03 Hpv chimaeric particle HK1198703A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA2011/08841 2011-12-01
ZA201108841 2011-12-01
PCT/IB2012/056912 WO2013080187A1 (en) 2011-12-01 2012-12-03 Hpv chimaeric particle

Publications (1)

Publication Number Publication Date
HK1198703A1 true HK1198703A1 (en) 2015-05-29

Family

ID=48534756

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112143.5A HK1198703A1 (en) 2011-12-01 2012-12-03 Hpv chimaeric particle

Country Status (18)

Country Link
US (1) US9771397B2 (https=)
EP (1) EP2785842A4 (https=)
JP (1) JP6228922B2 (https=)
KR (1) KR102013801B1 (https=)
CN (1) CN103890177B (https=)
AU (1) AU2012345443B2 (https=)
BR (1) BR112014012491A2 (https=)
CA (1) CA2850293C (https=)
HK (1) HK1198703A1 (https=)
IL (1) IL232584B (https=)
IN (1) IN2014DN03054A (https=)
MX (1) MX355352B (https=)
MY (1) MY184076A (https=)
PH (1) PH12014500466A1 (https=)
RU (1) RU2642287C2 (https=)
SG (1) SG11201401579UA (https=)
WO (1) WO2013080187A1 (https=)
ZA (1) ZA201403557B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3427755B1 (en) 2009-04-13 2020-10-21 INSERM - Institut National de la Santé et de la Recherche Médicale Hpv particles and uses thereof
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
MX385842B (es) 2013-09-18 2025-03-18 Aura Biosciences Inc Conjugados de partículas de tipo virus y uso de las mismas.
CN104531741B (zh) * 2014-08-22 2016-08-24 天津康希诺生物技术有限公司 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
CN105801704B (zh) 2014-12-31 2020-06-02 艾托金生物医药（苏州）有限公司 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用
AU2016308286B2 (en) 2015-08-18 2022-04-07 Rakuten Medical, Inc. Phthalocyanine dye conjugates and their storage
CN119564879A (zh) 2015-08-18 2025-03-07 乐天医药生技股份有限公司 用于光免疫疗法的组合物、联用及相关方法
WO2017075440A1 (en) 2015-10-30 2017-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Targeted cancer therapy
WO2018187515A1 (en) * 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
IL269986B2 (en) 2017-04-12 2024-06-01 Aura Biosciences Inc Targeted combination therapy
KR102797824B1 (ko) 2017-06-23 2025-04-17 버이뮨 아이엔씨. 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
SG11202106931PA (en) 2018-12-27 2021-07-29 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
MY207280A (en) 2019-07-19 2025-02-13 Sinocelltech Ltd Polyvalent immunogenicity composition for human papillomavirus
WO2021161179A1 (en) * 2020-02-10 2021-08-19 University Of Cape Town Plant produced bovine papillomavirus virus-like particles and pseudovirions
IL302190A (en) 2020-10-19 2023-06-01 Verimmune Inc Virus-induced preparations and methods for redirecting immune responses in the use of said preparations for cancer treatment
KR102821363B1 (ko) 2023-02-06 2025-06-13 영산대학교산학협력단 드론에 장착된 라이다 센서를 기초로 하는 수심 측량 시스템

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3863559B2 (ja) * 1994-05-16 2006-12-27 メルク エンド カンパニー インコーポレーテッド 乳頭腫ウィルスワクチン
AU760633B2 (en) * 1998-08-14 2003-05-22 Merck Sharp & Dohme Corp. Process for purifying human papillomavirus virus-like particles
US20020016372A1 (en) * 2000-07-31 2002-02-07 Allison Anthony Clifford Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury
WO2003068163A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
DK1506222T3 (da) * 2002-05-17 2009-07-06 Univ Cape Town Kimæriske, humane papillomavirus16 L1-proteiner omfattende et L2-peptid, viruslignende partikler fremstillet deraf samt en fremgangsmåde til at fremstille partiklerne
ATE541938T1 (de) 2005-04-29 2012-02-15 Univ Cape Town Expression viraler proteine in pflanzen
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
US9566323B2 (en) * 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
SG177269A1 (en) * 2009-06-25 2012-02-28 Glaxosmithkline Biolog Sa Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
WO2011077371A1 (en) * 2009-12-22 2011-06-30 University Of Cape Town Method for enhancing the expression of hpv l1

Also Published As

Publication number Publication date
IL232584B (en) 2018-10-31
IN2014DN03054A (https=) 2015-05-15
CA2850293A1 (en) 2013-06-06
AU2012345443B2 (en) 2017-10-26
BR112014012491A2 (pt) 2017-06-06
ZA201403557B (en) 2020-10-28
EP2785842A1 (en) 2014-10-08
RU2014126587A (ru) 2016-01-27
US9771397B2 (en) 2017-09-26
CN103890177A (zh) 2014-06-25
CA2850293C (en) 2019-10-08
CN103890177B (zh) 2016-03-09
MY184076A (en) 2021-03-17
KR20140098061A (ko) 2014-08-07
JP6228922B2 (ja) 2017-11-08
MX2014006520A (es) 2014-11-21
US20140377367A1 (en) 2014-12-25
AU2012345443A1 (en) 2014-04-17
WO2013080187A1 (en) 2013-06-06
SG11201401579UA (en) 2014-07-30
EP2785842A4 (en) 2015-11-25
JP2015500229A (ja) 2015-01-05
NZ622595A (en) 2016-04-29
PH12014500466A1 (en) 2022-05-11
RU2642287C2 (ru) 2018-01-24
MX355352B (es) 2018-04-17
KR102013801B1 (ko) 2019-08-23
IL232584A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
HK1198703A1 (en) Hpv chimaeric particle
PH12019502269A1 (en) Quinazoline derivatives for the treatment of viral infections and further diseases
HK1246183A1 (zh) Hpv疫苗
WO2012083017A3 (en) Controlled release oral dosage forms of poorly soluble drugs and uses thereof
CA2817005A1 (en) Rabies glycoprotein virus-like particles (vlps)
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
WO2012045089A3 (en) Methods for the treatment of allergic diseases
WO2011106376A3 (en) Use of microvesicles in the treatment of medical conditions
WO2012106356A3 (en) Virus-like particles and methods of use
WO2013098655A3 (en) Vaccines directed against human enteroviruses
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
HK1217092A1 (zh) 治疗性化合物及其用途
WO2013006569A3 (en) Herpes virus vaccine and methods of use
EP2444103A4 (en) UTERUS COLON CANCER VACCINE
EP2978449A4 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
EP2601967A4 (en) MEDICINE FOR PREVENTING AND TREATING HIV-RELATED OR HIV-RELATED DISEASES, INCLUDING AIDS
WO2011064630A8 (en) New clone of newcastle disease virus, its manufacture and its application in the medical treatment of cancer
WO2010088527A3 (en) Peptides and nanoparticles for therapeutic and diagnostic applications
WO2010138419A3 (en) Materials and methods for treating viral infections
HK1225972A1 (zh) 利用拉喹莫德来延缓亨廷顿氏病的进展
WO2011100234A3 (en) Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods
HK1216721A1 (zh) 治疗肝脏疾病或病状的用途和方法
WO2012036437A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련 질환 예방 또는 치료용 조성물
WO2012123924A3 (en) Antimicrobial composition including at least one or more aggregation(s) silver particles
WO2014145289A3 (en) Compositions derived from sweet potato greens and methods of preparation and use